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Chagas disease is the main cause of heart failure and sudden death in the Western Hemisphere. 
The literature of the last decades reported on the changing epidemiological profiles of Chagas 
disease, which now threats the human population in the cities. The exodus of the Latin America 
people to the Northern Hemisphere explains the growing concern in countries where the 
transmission of Trypanosoma cruzi was accidental or transferred from a mother to her offspring. 
Herein, we present the evidence of the possible acquisition of the T. cruzi infection by sex. The 
staggering demonstration of the transmission of the T. cruzi infections from males and females to 
naïve mates by intercourse introduces substantial changes in the surveillance of the Chagas 
disease. Notably, the sexual transmission of the T. cruzi introduces changes in the concepts of 
medical care, prevention and control; specifically, the risk for the vertical transfer of the parasite-
induced kDNA mutations, underpinning the genetically driven autoimmunity, inheritance, and 












ratios of morbidity and mortality. In this regard, the endemics require much paradigm research with 
new approaches and innovation technologies, aiming at its control. For example, the recent 
knowledge anticipates useful measures for preventing the potential forthcoming pandemic Chagas 
parasites. A long-lasting multicenter research program is needed for creative, drug discovery for 
curtailment of Chagas disease. Meanwhile, the prevention shall rely on the education, information, 
and communication program for health.  
 
 





ATPase : adenyltriphosphatase.  
Benznidazole and Nifurtimox : nitroderatives used for the treatment of Chagas disease.  
CCD : chronic Chagas disease.  
CSB : kinetoplast minicircle constant sequence block.  
CYP5128–30 : fenarimol herbicide azole inhibitor of T. cruzi.  
EICH : education, information, communication for health.  
elF2a : elongation factor 2a.  
ELISA : enzyme-linked immunosorbent assay.  
IFI : immunofluorescence indirect.  
ik2 : eukaryote kinase subunit 2.  
EMBL : European molecular biology laboratory.  
ERV : endogenous retro virus.  
LINE-1 : long interspersed nuclear element-1.  
MAL-R : long terminal repeats.  
NAT : nucleic acid test.  
nDNA : T, cruzi nuclear DNA.  
kDNA : T. cruzi mitochondrion kinetoplast DNA;  
PI3K : phosphate inositol 3 kinase.  
PCR : polymerase chain reaction. 
32




The Kinetoplastid flagellates in the Family 
Trypanosomatidae (from greek; trypanon, auger; 
soma, body) include Trypanosoma cruzi, the 
agent of the American trypanosomiasis [1,2]. The 
T. cruzi belongs to the Stercorarian group of 
flagellates that accomplishes its life cycle in the 
gut of the invertebrate host; the insect sucks in 
the blood trypomastigote, which transforms into 
epimastigote in the foregut and reverts to 
infective metacyclic trypomastigote in the hind 
gut. The requirement of an invertebrate host for 
completion of the protozoa lifecycle ascribes to 
the beginning of the T. cruzi enzootic infection of 
mammals that dwell in the American Continent 
[3-5]. The enzootics include reservoirs of the 
orders Marsupialia, Edentata, Chiroptera, 
Carnivora, Artiodactyla, Rodentia and Primates, 
upon whom triatomine bugs prey and transmit T. 
cruzi [5-7]. The spreading of the T. cruzi 
infections requires a broad diversity of triatomine 
vectors and mammalian hosts [5-10]. 
 
In past decades, the epidemiologic profiles of 
American trypanosomiasis and Chagas disease 
underwent drastic changes due to the rural 
exodus and, therefore, now they become an 
emerging urban problem [6-18]. The changes of 
the profiles follow pattern of the migration of T. 
cruzi-infected people from the South America 
continent and their settlement in the Northern 
Hemisphere [18].  
 
Herein, we review the literature that describes 
the recent change of epidemiologic profiles of the 
Chagas disease. The review integrates the 
available data and information in men and in 
laboratory animals with growing concern about 
new technologies for preventing Chagas disease 
that threatens the people worldwide [7-19]. With 
this respect, this review article presents up-to-
date parasitological, clinic, cell biology, 
immunologic, genetic, pathology and the scanty 
epidemiologic information for the attention of the 











authorities. The aim of this review is to spurring a 
long-lasting program, aiming at a new drug to 
treat the carrier and to eradicate the endemic T. 
cruzi infections and control of the sexual 
transmission of the T. cruzi [18-20]. This review 
anticipates that the curtailment of Chagas 
disease needs international solidarity and 
multicenter research groups to undertake 
efficacious, creative, prevention paradigm 
achievements. In this regard, a mass-media 
Education, Information, and Communication for 
Health (EICH) program to prevent Chagas 
disease in the forthcoming decades can no 
longer be neglected.  
 
2. TRANSMISSION ROUTES  
 
The main public health problem initiated, 
possibly, with the accidental triatomine bug-
transmission of the T. cruzi infections to human 
[21-23]. However, the route for the bug hindgut’s 
trypomastigote entry into the host’s body and 
parasitic cell growth, is cumbersome: i) in the 
absence of systematic information, it is assumed 
that most acute T. cruzi infections stem from 
triatomine bug’s bite, supposedly, in hinterland 
endemic areas; ii) incomplete knowledge about 
the bug’s feces T. cruzi contamination ratios in 
countless ecotypes of the America continent [24-
30]; iii) triatomine bug’s night habits, frequency of 
accomplishing a full meal and ratios of T. cruzi 
contamination, is mostly unknown [27-29]; iv) 
quick feeding ability to obtaining a full blood 
meal, distension of the abdomen and bug 
immediate defecation, remains to be determined 
[27-29]; v) triatomine bite site scratch-induced 
allergic reactions and vase dilation promotes 
bug’s proboscis cannulating and suck-in a full 
blood meal, defecation and spread of the 
excreta, and the T. cruzi contaminates the 
human body [27-29]; nonetheless, in the 
absence of an allergic reaction and vase dilation 
the prey does not aware about the annoyance 
that incites the scratching, which renders much 
difficult a full completion of the time consuming 
blood meal, defecation and possible 
contamination of the host’s body [24-31]; vi) the 
frequency of the hypersensitivity lesion at the 
port of entry of the parasite in the skin 
(Chagoma) or in the eye conjunctiva (Romaña’s 
sign) is, possibly, less than circa 1 out of 1000 
acute infection [5,6].  
 
The spectrum of drawbacks translates an array 
of difficulties towards collecting family information 
about bug’s transmitted T. cruzi infections to the 
human population. However, the early 
recognition of the vector-transmitted T. cruzi 
infections posited first in the rank among routes 
of the T. cruzi contamination of humans [18,23]. 
In this regard, further investigation is needed to 
determine whether the ratios of T. cruzi-positive 
triatomine infestations correlate to the prevalence 
of Chagas disease in the cities.  
 
The acquisition of the T. cruzi infections per os is 
the most ancient route for the T. cruzi 
contaminating the insectivorous mammals’ 
reservoirs in the wilderness [31-33]. A few 
epidemiologic studies refer to the outbreaks of 
acute Chagas disease in humans, possibly, by 
imprudent ingestion of food contaminated with 
the triatomine bug’s feces [2,32,33]. Next, the 
acquisition of the T. cruzi infections by blood 
transfusion is reported; lately this route of the 
infection acquisition is considered, carefully, as 
well in several countries of the Northern 
Hemisphere [34-36]. Occasionally, the T. cruzi 
infections are acquired by accident in the 
laboratory and by organ transplantation [36].  
 
The transmission of the T. cruzi from the Chagas 
mother to her offspring is an important route of 
the infections in humans [36-38]. The congenital 
transmission of Chagas disease refers to the in 
uterus infection acquisition by the offspring. 
However, pregnancy depends upon partnership 
and male contribution to the in uterus T. cruzi 
infections awaits investigation. In the course of 
the pregnancy, the chagasic woman may 
undergo early embryo resorption, miscarriage, 
death birth, or neonatal death; live births can 
either be T. cruzi-infected or infection-free, 
healthy baby. Additionally, the infection-free, 
healthy progeny can inherit the T. cruzi 
mitochondrion minicircle kDNA sequences into 
the genome [7].  
 
3. CHAGAS DISEASE 
 
The routes of acquisition of the T. cruzi infections 
impose either the silent American 
trypanosomiasis or the clinically manifested 
Chagas disease. Fair accounts of the prevalence 
of those patients are missing and, therefore, the 
epidemiologic reports on morbidity and mortality 
due to the T. cruzi infections are rather 
inconclusive [6]. In the absence of disease 
manifestation, chronically infected humans are 
intermediate-phase carriers or reservoirs of the 
T. cruzi infections [7,37,38]. A majority of 
chronically infected individuals remains in the 
intermediate phase and their life expectancy is 











The field studies show that some chronically 
infected individuals develop chronic Chagas 
disease (CCD) usually over ~30 years after the 
acquisition of the T. cruzi: 94.5% are cases 
affected by heart trouble, among which 38.5% 
die suddenly, and 56% succumb to heart failure 
[6,7]. Sudden deaths are associated with 
arrhythmias and heart rate turbulence. In 
addition, megaesophagus and megacolon are 
revealed in 5.5% of chronically infected people. A 
gamut of neurologic syndromes and clinical 
dysfunctions are manifestations of Chagas 
disease, yet, scarcely studied [7-10]. Moreover, 
CCD clinic and pathologic features, which are 
indistinguishable from idiopathic inflammatory 
dilated cardiomyopathy, have the differential 




4.1 Trypanosoma cruzi in the Blood 
 
The direct microscopic demonstration of T. cruzi 
in the blood is recorded in the early phase of the 
infection. Also, the parasite is detected by 
concentration methods, such as blood culture 
and xenodiagnoses (having a clean bug to feed 
upon the patient’s blood). For the epidemiologic 
surveys, however, these diagnostics approaches 
are out of reach by a majority of the T. cruzi 
intermediate phase chronically infected 
population, in a lack of late clinical CCD 
manifestations. 
 
4.2 Immune Diagnosis 
 
In the absence of a direct demonstration of the T. 
cruzi in patient’s blood the diagnosis relies on 
searches for the specific antibody. The acutely 
infected people are recognized by detecting IgM 
antibody class or IgG serum conversion usually 
after the second week of infection. Currently, 
highly sensitive, but relatively less specific 
indirect hemagglutination, enzyme-linked 
immunosorbent assay (ELISA), and indirect 
immunofluorescence (IFI) tests are routinely 
used [41-42]. However, none of these assays 
affords complete sensitivity and specificity, 
because the host's immune system sees a 
plethora of parasitic antigens and clonal selection 
of immune responses [6,7,41,42]. A word of 
caution is required because a grey zone of 
inconclusive assays that yield cross-reactive 
antibodies in the serum of patients with 
Leishmania sp., Mycobacterium leprae and M. 
tuberculosis, Treponema pallidum, or 
autoimmune diseases [7,42]. Largely, the 
employment of recombinant or synthetic peptide 
antigens diminishes the sensitivity of the assays, 
and these concerns bear practical consequences 
[38,39]. With this respect, caution is required in 
order to avoid an accidental T. cruzi-
contaminated blood transfusion. The health 
systems should no longer rely solely on testing 
the humoral immunity specific T. cruzi antibody 
[7,41-47]. Nonetheless, the electrocardiograph 
recordings in series of patients from endemic 
regions show cases with the positive serum anti-
T. cruzi IgG, increased heart size in the chest X-
rays, and arrhythmias with features of chronic 
Chagas disease [48-50]. 
 
4.3 Nucleic Acids Test (NAT)  
 
The accuracy of the diagnoses of the T. cruzi 
infections to the point-of-care for the assessment 
and curtailment of the epidemics, and as well for 
the health care delivery to thousands of people 
aggravated by the yet incurable Chagas disease, 
is fundamental [43-47,51,52]. Therefore, the 
diagnosis of the sexually transmitted infection 
requires the flagellate protozoa footprint [38-40, 
43-47], because the specific IgG antibody is 
absent in the immune tolerant progeny of the T. 
cruzi-infected parents [38,51-54]. The immune 
tolerance showed in the chicken model system 
refractory to the T. cruzi infection after the 10
th
 
day of incubation [38,47,51-54]. The chicks 
hatched from T. cruzi-inoculated eggs, which 
grow to adult life, do not raise specific antibody 
(Y immunoglobulin) after challenge with the 
formalin killed parasite [53,54]. 
 
The NATs detect T. cruzi nuclear DNA (nDNA) 
and its kinetoplast DNA (kDNA) in somatic cells, 
and as well in germ cell line of the reproduction 
systems immune privilege organs [38,43-47,51-
54]. Moreover, the NAT-nDNA test is an 
indispensable condition for the diagnosis of T. 
cruzi infection in immune-tolerant patients, in the 
absence of the specific antibody. The 
development of throughput digital PCR platforms 
[47] needed to testing blood donor candidates, 
so as deferral of those NAT-nDNA positive blood 
donors, and to surveying accurate prevalence 
and correct information on the epidemiology of 
American trypanosomiasis and Chagas disease. 
 
In so far, the NAT polymerase chain reaction 
(PCR) is the basis for research laboratories 
diagnosis of the T. cruzi infection and detection 
of congenital Chagas disease at birth [38,43-46]. 
Its employment ensures tidy laboratory practices 











repetitive sequences in the flagellate protozoa, 
showing homology with human chromosomes; 
and throughput platform required for large-scale 
epidemiologic surveys. A gamut of nDNA primer 
sets is available for in-house PCR diagnosis of 
the T. cruzi infections with variable sensitivity and 
specificity [38, 44,47]. The Tcz1/2 primers set 
that targets a 188-nt telomere DNA repeat in the 
T. cruzi genome [48] are used in the family-
based studies [38-51]. The amplicons resolved in 
agarose gels and transfer to positively charged 
nylon membranes hybridize to the 188-nt α 32p-
dATP labeled probe, subsequently subjected to 
X-Rays film exposure during variable periods. 
The positive amplicons are subjected to cloning 
and sequencing. The bioinformatics analyses 
reveal the 188-nt nDNA footprint in the blood and 
in the semen samples. This in-house NAT is the 
point-of-care diagnosis of an active T. cruzi 
infection [38, 43-46]. Therefore, gold standard 
NATs are required to guarantee integrity, purity, 
and adequacy of blood bank supply donor 
deferral and pathogen inactivation of blood 
components. These efforts should be supported 
by the health care networks for prevention of an 
emerging T. cruzi threat; laboratory procedures 
quality control assessment by skilled personnel 
are needed to monitor all steps prior to the blood 
transfusion and for delivery of the health care. 
Additionally, the importance of the NAT tests for 
diagnosis of the T. cruzi infection and CCD 
cannot be underemphasized because the cross-
section epidemiological surveys based on the IFI 
serological assessments of the specific antibody 
determine neither the accurate prevalence of the 
T. cruzi infections nor the ratios of the parasite 
sexual transmission in the human population [38, 
41-46]. 
 
5. TRANSFER OF KINETOPLAST DNA 
(kDNA) FROM AMERICAN 
TRYPANOSOMES TO HUMANS 
 
The studies showed transfer of the mitochondrial 
DNA (kDNA) minicircles sequences from                        
T. cruzi to the rabbit’s chromosome [56], and it 
was further showed that the Chagas rabbit 
progeny retained the protozoan minicircle 
sequence mutation into the genome [7, 52-56]. 
The chicken family studies spurred the human 
families’ investigations on the transfer of the 
kDNA sequences from Chagas disease parents 
to their progeny [54-56]. The founders of study 
families showed kDNA minicircle sequences 
integrated into the Long Interspersed Nuclear 
Element-1 (LINE-1, equivalent to CR1 in the 
chicken) of the human genome. In addition, the 
kDNA minicircle sequences integrated at various 
locations, such as structural, cell growth and 
differentiation, immune responses and at 
important biochemical pathways checkpoint 
genes [52-56]. 
 
The development of Chagas heart trouble in the 
chronically infected human population is an 
ominous sign because the cases succumb to the 
autoimmune inflammatory cardiomyopathy either 
suddenly or in the range of six months to two 
years after the beginning of clinical symptoms 
and failure, and, therefore, it is unusual to find 
those cases in a cross sectional field study. 
Nevertheless, the family study showed the 
accumulation of a minimum of 4 to 8 kDNA 
mutations into the retrotransposable LINE-1 
located at various chromosomes of CCD cases 
with clinically manifested heart insufficiency [7, 
38, 52-56]. 
 
The chagasic parental (F0) vertically transferred 
the T. cruzi kDNA minicircle sequences to                     
the F1 and F2 progeny, which integrated                         
into the genome [38]. Additionally, the                    
families study population showed that                    
somatic cells had the T. cruzi NAT-nDNA positive 
tests in family members and that sperm                   
donors had the active T. cruzi infection.                    
These findings suggest that intercourse is a 
sustainable route for transmission of the T. cruzi 
infection [38]. The clinic and epidemiologic 
importance of these findings address to the 
flagellate life-long infection, the overtime 
accumulation of the mitochondrion kDNA 
minicircle mutations and Chagas disease 
multifaceted manifestations, in which parasite-
induced mutations underpinning the genetically 
driven autoimmune pathogenesis, remarkably, 
features of host-parasite relationships and 
sprouting human disease.  
 
6. SEXUAL TRANSMISSION OF THE 
AMERICAN TRYPANOSOMES 
 
In the last decades, the growing number of 
Chagas disease in the Northern Hemisphere 
inhabitants ever exposed to the insect vectors 
suggests the possibility of acquisition of the T. 
cruzi infections by the intercourse [7, 38]. In this 
regard, the T. cruzi infections encrypted in 
immune privilege body niches, in the absence of 
inflammatory infiltrates, make the grounds for the 
parasitic growth [57-63] in the reproductive 
organs (Fig. 1) and, thus expelling the protozoan 
in the semen (Fig. 2) and in the uterine 











6.1 Family Study 
 
The timely demonstration of the sexually 
transmitted T. cruzi in families’ document the 
epidemic bursts of the infections in the 
population that received health care at the 
Center for Chagas Disease Surveillance. Among 
individuals in the families, there were cases of 
the acute T. cruzi infections showed by direct 
demonstration of the blood trypomastigotes. 
However, the epidemiologic history of the study 
population revealed the absence of the 
triatomine-bite transmission of the infections and, 
also, the other routes of the infection-acquisitions 
were denied.  
 
In the family study, each acute case treated with 
the anti-trypanosome nitro derivative 
benznidazole (5 mg/kg/day) for 60 days, and all 
family members received health assistance for 
five years. The individuals in the families yielded 
blood samples at 1, 2, and 3 years set points for 
serum and DNA collection. Interestingly, the 
NAT-nDNA test was consistently positive in 76% 
independent assessments of blood samples 
collected at three different set points: among 
these, 28.4% tested IgG positive. This broad 
discrepancy explained by the immune tolerance, 
in the absence of the antibody in the majority of 
NAT-kDNA positive individuals, since the 
sexually transmitted T. cruzi could reach the 
early embryo before the development of the 
immune system [38,52-57]. Additionally, the 
NAT-kDNA test was positive in 92.6% family 
members (EMBL HG008116 to HG008708). The 
difference between the results obtained by the 
NAT-nDNA and the NAT-kDNA approaches 
addresses to the mutations resulting from the 
integration of the minicircle DNA sequences into 
the human genome in the absence of live T. cruzi 
infections. (Fig. 3). 
 
In the absence of the T. cruzi antibody, the NAT 
analyses of the germ cells collected from 
subjects in the family study confirmed the 
experimental data [38,52-56] showing that the T. 
cruzi infections acquired during early embryo 
growth do not bear the specific antibody, 
whereas those acquired during fetal development 
do not undergo immune-tolerance and, thus 
reveal the specific antibody. These analyses 
showed the T. cruzi nDNA- and kDNA-specific 
bands in the somatic cells of the blood and in the 
haploid semen samples examined [38, 57-63] 
(Fig. 4). The data that suggest the sexual 
transmission of the T. cruzi infections confirmed 
by other experiment, in which the injection of 100 
µl aliquot of NAT-nDNA positive Chagas patient’s 
semen into the peritoneal cavity or its infusion 
into the vagina of mice documented the infectivity 
of the T. cruzi present in the human ejaculate: 
one month thereafter, the growing T. cruzi 
amastigote nests appeared in the heart and 
skeletal muscles, and in the lumen of the vas 
deferens and uterine tube (Fig. 4). 
 
The early epidemiology based serological 
surveys conducted in the spare individual 
estimate that the prevalence of the T. cruzi 
infections averages 7 ± 3 percent of the Latin 
America population [6,49]. The family study NAT 
assessments revealed much high ratios of the T. 
cruzi infections in male and female family’s 
founders and progeny mates [38,52-56]. 
However, the so-called congenital transmission 
of the infection means that the woman only bears 
for the vertical T. cruzi transmission to her baby. 
Certainly, such prejudice definition is in the lack 
of scientific understanding, because it omitted 
the inevitable roles played by both mates during 
the bi-partisan sexual reproduction [38]. With this 
respect, further family-based studies at various 
ecosystems are required to determine the role 
played by the mate’s sexual intercourse in the 
transmission of the infectious agent retained in 
the immune privilege reproductive organs. The 
immune privilege is the absence of destructive 
inflammatory reactions to microbes’ antigen 
loads in important body structures in the brain, 
eyes, and reproductive organs, accomplishing 
sensitive functions, reproduction, and the species 
survival [64, 65]. The immune privilege sets free 
the T. cruzi growth in the organs of the 
reproduction, whereas the immune tolerance [64]
 
prevents the immune system rejection of the 
parasite antigen, because it is recognized as a 
component of its own body since early embryo 
life. 
 
6.2 Mouse Model System 
 
The pathology searches documented a gamut                   
of the T. cruzi amastigote nests in the                            
mouse uterine endometrium, ovary theca                  
cells, and testicles’ Sertoli cells and in the lumen 
of the seminiferous tube, and in the epididymis, 
seminal vesicles, prostate, and ureter [57-63]. 
Actually, the inoculation of the T. cruzi from the 
hindgut of a triatomine bug incited the replicative 
flagellates’ growth [57] in the recipient mouse 
ejaculates (Fig. 2). Furthermore, the T. cruzi 
infections were documented upon Chagas 
patient’s semen inoculation or infusion in naïve 













Fig. 1. The Trypanosoma cruzi infection in the seminiferous tube of a boy with the acute 
Chagas disease. Notice the round amastigote forms in the gonia blasts and clumps of 
amastigotes and trypomastigotes in the lumen of the tube (arrows). Bar, 10 µm. 




Fig. 2. The Trypanosoma cruzi parasitic forms in the semen ejaculate of acutely infected mice. 
The arrows indicate amastigote (A) within the head of a spermatozoan; free amastigotes (B) 
and trypomastigotes (C and D); and the epimastigote forms (E and F) in the semen ejaculates 
(arrows). Giemsa stained smears. Bars, 10 µm. Reprinted with permission from the Author and 
the Publisher [57] 
 
 
Fig. 3. The diagnosis of the Trypanosoma cruzi infections made by PCR and Southern 
hybridizations. Notice the nuclear DNA (nDNA) bands in 11 Chagas patients with the live 
infections, whereas 21 family members showed the mitochondrial DNA (kDNA) bands. 













Fig. 4. The infectivity of the Trypanosoma cruzi from the human semen ejaculates upon aliquot 
instills into the peritoneal or into the vagina of naïve mice. Left) the T. cruzi amastigotes clump 
in the lumen of the vas deferens. Right) the T. cruzi amastigotes swarm epithelial cells of the 
uterine tube (insert, dividing amastigotes). Bars, 10 µm. Reprinted with the permission from 
the Authors and the Publisher [38] 
 
Moreover, family studies about the T. cruzi-
infected male and female mice showed the 
transmission of the protozoa flagellates to naïve 
mates upon intercourse. In those experiments, 
each breeding pair placed in one cage inside a 
safe box avoided escaping. In experimental 
group-A, 10 T. cruzi-infected males mated with 
10 naive, control females. In experimental group-
B, 10 T. cruzi-infected females mated with 10 
naive, control males [38]. After breeding, groups 
A and B mates’ yielded NAT-nDNA bands that is, 
the naive mates readily acquired the T. cruzi 
after the sexual encounter. The triplicate groups 
of independent experiments also showed that 
naive female or male mouse that sexually mated 
with a T. cruzi-infected male or female acquired 
the infection. Those nDNA-positive founders (F0) 
generated progeny F1 and F2 that they raised 
until six weeks of age. The founders' (F0) 
transmitted sexually the infections to F1 progeny 
as shown by the nDNA-positive bands. The 
breeding of these nDNA-positive mates 
generated F2 progeny, which showed the nDNA 
bands that indicate the vertically acquired 
infections. In these experiments, 58.6% of the 
progeny had the NAT-positive nDNA assays, and 
22% of the progeny had anti-T. cruzi antibodies. 
The results confirmed the absence of the specific 
antibody in a majority of F1 and F2 mice (78%) 
that bore vertical T. cruzi infections by 
intercourse. After that, the tissue sections taken 
for microscopic examination showed the T. cruzi 
in the reproductive system of those mice [38]. In 
summary, those experiments suggest that few 
offspring (22%) of chagasic mates had the T. 
cruzi-specific antibody, probably, because the 
infectious agent reached the fetus with a mature 
immune system. 
 
7. DRUG DEVELOPMENT  
 
The strategic for the treatment of Chagas 
disease should take into consideration that single 
infective T. cruzi initiates a lifelong infection [7]. 
Regardless of the route of the infection, after 
several cycles of division, the T. cruzi ends up in 
the reproduction organs immune privilege sites 
where it grows [38,64]. The amazing capability of 
the T. cruzi to thrive in the immune privilege 
mammalian reproductive system, so as to reach 
out the route to contaminate the host during 
intercourse; the species survival prevail 
transmission by sex and warrants the T. cruzi 
anthropozoonosis, and, therefore, this new 
concept shall guide the preventive medicine and 
public health measures for the control of 
American trypanosomiasis. This observation 
makes the absolute need of the parasite 
eradication in order to accomplish cure of 
Chagas disease and prevention of the sexually 
transmitted infections. 
 
The lead drugs used for the treatment of the T. 
cruzi infections are nitro- derivative compounds 
nifurtimox [4-(5-nitro-phurylideneamino-) 
tetrahydro-4-4-1, 4-thiazine-1-1-dioxide], and 
benznidazole [N-benzyl-2-nitro-
imidazoleacetamide) [39-40, 49, 50, 81-84]. Both 
drugs achieve elimination of the T. cruzi 











infections in experimental animals and in man 
[38,40,66,67], possibly, because after-treatment 
non-phagocyte growing nest sustains the 
persisting parasite infection. The nitro-derivatives 
toxicity includes mutagenic, teratogenic, 
carcinogenic and sterilizing activities [68-76], 
which relies on the pteridine reductase activity 












H2O2 that bind to macromolecules and DNA. The 
drug toxicity targets the parasite and the 
mammalian host cell [7-79].  
 
8. NEW DRUGS FOR PREVENTING 
CHAGAS DISEASE 
 
The Chagas disease reported in five continents 
[25-37] has brought much attention from private 
and public organizations. In this new look, 
searches for safe, efficacious, low-cost drugs to 
curtailment of the epidemics needed. 
Consistently, the T. cruzi biochemical pathways 
checkpoints described herein suggest possible 
targets for drug development. The clinical trials 
with the 14α-demethylase (CYP51) that 
catalyzes the removal of the 14 α-methyl group 
from the scaffold revealed that posaconazole and 
ravuconazole inhibitors of sterol biosynthesis 
undergo treatment failure above that for 
benznidazole-treated patients [38,43-50]. The 
anti-trypanosome activity of lapachone-based 
1,2,3-triazole naphthoquinones derivatives 
presented IC50/24 h 80.8 values at 6.8 and 8.2 
μM activity which is above that of the anti-T. cruzi 
drug benznidazole. The nitro heterocycles 
fexinidazole prompted the discovery of the 
oxazole AN4169 (SCYX-6759) with anti-T. cruzi 
activity in a mouse model. Other leads 
derivatives of the herbicide fenarimol, which is an 
azole inhibitor of T. cruzi CYP5128–30. 
Meanwhile, the nitro derivatives benznidazole 
and nifurtimox registered for treatment of Chagas 
disease in Latin America [80-82]. In the countries 
of the Northern hemisphere the prescription of 
these drugs requires license from the health 
authorities. 
 
Actually, the sustainable search for compounds 
from medicinal plants and drug development to 
kill the T. cruzi is needed, because most 
antibiotics derived from natural metabolites used 
for defense, reproduction, and survival [82-83]. 
The use of throughput biotechnologies for the 
systematic procurement and identification of 
active molecules in plants from various 
ecosystems, showing enormous biodiversity shall 
enhance the chance for obtaining a top lead drug 
without toxicity to eradicate the T. cruzi for 
prevention and treatment of Chagas disease. 
This is a milestone research endeavor. 
  
9. PREVENTING AMERICAN 
TRYPANOSOMIASIS AND CHAGAS 
DISEASE 
 
Over three decades the World Health Authorities 
were at odds with the devastating acquired 
immunodeficiency syndrome (AIDS). The 
epidemics caused the death of unaccountable 
people all over the world, in the lack of the 
specific diagnosis, except for the variety of 
opportunistic infections in the debilitating immune 
tolerant organism. Otherwise, International 
Health Authority Organizations consider Chagas 
disease minor epidemics that affect the poor 
people of Latin America, and the local Health 
Institutions claim that the disease is under 
control.  
 
Meanwhile, the Chagas disease high morbidity 
and mortality ratios are growing burden upon the 
health systems worldwide and, therefore, it 
should not be neglected anyway (21-37). On the 
one hand, the Chagas disease unperceived 
epidemics [84-85] require the attention of the 
health systems because the potential of 
spreading the re-emerging transmission routes, 
including the sexually transmitted T. cruzi 
infections can no longer be underemphasized. 
On the other, the trophic network that enmeshes 
the T. cruzi in countless ecotypes in different 
ecosystems [4, 8], including the underground 
[86], embracing many species of insect vectors, 
most of which are not used to domiciliation are 
not susceptible to insecticides, and, therefore, 
the anthropozoonosis cannot be eliminated by 
the vector control strategy. To approach the 
magnificent problem the health personnel and 
scientists agree that time-consuming, 
unprecedentedly sustainable investigation 
programs are necessary, in order to create the 
knowledge new order to combat this threatening 
epidemic, urgently. 
 
9.1 Education Information and 
Communication for Health (EICH) 
 
The EICH program, aiming at the control of the 
transmission of the T. cruzi infections, is needed. 
The population is entitled to know about all 
routes of transmission of the T. cruzi infections: 
a) sexually transmitted; b) accidental 
contamination of health care workers and of 











transfusion not deferred by the antibody assays; 
c) imprudent ingestion of contaminated food; d) 
insect-vector transmitted T. cruzi infections, 
which are limited to the American Continent. The 
a) and b) modes of transmission of the infections 
are prone to occur in the five continents. The 
basic EICH program to prevent the transmission 
of the silent T. cruzi infections shall take some 
experience of from AIDS mass-media guidelines, 
and the NAT nDNA exam performed early for the 
detection of the two weeks period in which the 
acute infections run in the absence of the specific 
antibodies [38,87,88]. 
 
The EICH program should aim at the control of 
the epidemics through the involvement of the 
people in the community with the knowledge 
about the trophic networks that associate the 
insect vectors reservoirs with over one 
thousands mammal hosts in the indomitable 
nature [8]. The information about the several 
dozens of the insect species (triatomine bugs) 
transmitters of the T. cruzi, thriving in countless 
ecotypes, hiding away under tree’s bark, in the 
mammals and in the birds’ nests, as well under 
the rocks, and in burrows in the undergrounds, 
should be promptly delivered to the population [8, 
11,17,18]. They should know that a few 
triatomine bug species are susceptible to 
domiciliation, and those are main targets for 
elimination, to assure the family’s protection at 
the household. 
 
The EICH guidelines shall sustain the 
knowledge, saying that the education tempers 
the best health agent in the community. 
Additionally, to inform the people in the 
community about the genotoxicity of the nitro-
derivative pyrethroid pesticide sprayed in the 
house regardless of the inhabiting infants and 
adolescents [68,69]. In the case, the health 
authorities believe it is necessary to spray the 
pyrethroids an informed consent form with the 
Family Leader signature is a prerequisite for the 
insecticide spraying, in the household free of 
infants and adolescents. 
 
A formidable effort is required for developing the 
EICH program aiming at the grass roots of the 
populations under potential exposures to the T. 
cruzi infections. Furthermore, the effective 
prevention measures shall sustain the concept 
that the EICH efficacy is a lot more protective of 
the family in the household than the spray of 
pesticides that do not reach most blood fasting 
triatomines dispersed in the hideaway 
environment. In addition, the citizen under the 
benefits of the EICH program shall fight to 
eliminate the nasty triatomine bug inside his 
house. 
 
The citizens shall be informed about the constant 
increasing ratios of the T. cruzi infections in Latin 
America and worldwide. The continuous exodus 
of the people from Latin America to the Northern 
Hemisphere partly explains the many cases of 
the Chagas disease in the regions where the 
insect-vector does not exist. Meanwhile, the 
usefulness of the EICH program at school and at 
social organizations, with emphasis on the 
sociology, biological and health sciences, and 
mass–media communication, shall prevail 
worldwide in order to prevent the sexual 
transmission of the infections [38,85]. Moreover, 
unprecedented drug-discovery program needs 
for the parasite eradication and prevention of the 





The trypanosome survival in invertebrate and in 
vertebrate animals include fine strategic 
checkpoints such as hiding away underground 
and association with countless ecotypes out of 
reach of skilled health personnel and 
insecticides. The plethora of countless factors, 
playing important roles in the multi-factorial chain 
of events related to transmission of the T. cruzi 
infections requires further studies in the 
laboratories and in the field. Meanwhile, the 
complexity of the T. cruzi life-cycle does not 
sustain the belief that currently used strategies 
are good enough for preventing the T. cruzi 
infections so as to safeguard the human 
population [8]. Such epistemological definition is 
essential because not yet defined cumbersome 
factors have been brought into play by an 
enormously complex chain of events and the T. 
cruzi encroaches in major ecosystems. The 
discovery of novel preventive and control 
strategies should be further investigated by 
scholars, before propagating the control of the T. 
cruzi infection and Chagas disease is achieved. 
 
Actually, the sexually transmitted T. cruzi 
infection undergoes life-long encryption in the 
body, and, in the absence of clinic 
manifestations, the patients do not seek 
preventive medical care. In the absence of a 
drug to eradicate the T. cruzi infection, the EICH 
program is the corner stone for preventing the 
sexual transmission of the American 











11. CONCLUDING REMARKS 
 
The EICH actions in the American Continent, 
concerning the prevention of the triatomines from 
close contact with the human population should 
be conducted directly in communities, 
elementary schools, churches and social clubs, 
and reinforced by social marketing and mass 
media communications. The population should 
be promptly informed about the modes of 
transmission of the T. cruzi infections that pose 
daily threats to human health. A realistic and 
affordable control of the sexually transmitted T. 
cruzi infections and the curtailment of Chagas 
disease rely on a robust EICH program.  
 
The EICH preventive actions to halt the 
American trypanosomyasis and Chagas disease 
spread worldwide should be on the time table 
because the sexual transmissions of the T. cruzi 
infection run simultaneously with the transfer of 
the parasitic kDNA to the human genome. This 
frailty introduces a significant change in the 
concept of public health, and preventive 
medicine [7,38,67]. The silent parasite-induced, 
genetically driven autoimmunity [38,64-66,67] 
associates ubiquitous clinical manifestations with 
high ratios of morbidity and mortality several 
decades after the infection acquisition, and, 
therefore, a conjunction of measures is 
necessary to control the Chagas disease and its 
potential to become pandemic: 
 
1. Chagas disease is a global problem that 
requires international solidarity, consortia, 
and exchanges of expertise in order to 
provide the means for protection of the 
population under risks of acquisition of the T. 
cruzi infections. 
2. Education, Information, and Communication 
mass-media program (EICH) undertaken, 
soon is the best, in order to obtain full 
compliance from the people’s community, 
similar to that employed to control HIV-AIDS 
epidemics. 
3. Safe new drugs needed to eradicate the 
cryptic T. cruzi infections: i) to treat all the T. 
cruzi-infected people, so as to prevent the 
sexual and the accidental modes of 
transmission of the infections. ii) To arrest 
the cardiomyopathy: pre-empt the severe 
Chagas heart disease case, before the killing 
of sick bone marrow progenitors of the 
effector immune lymphocytes before healthy 
bone marrow transplantation [64,65]. 
4. Development of throughput digital PCR 
platforms for assessing the population under 
risk of acquisition of the T. cruzi infections, 
so as deferral of NAT-nDNA positive blood 
donors. 
5. The health personnel should share 
responsibility with the community leaders 
about the target-directed limited spraying of 
the pyrethroid insecticide in the triatomine 
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